Mkc-1 clinical trials
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 1998
How each study uses mkc-1 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- MKC-1
- 9
Studies by the year they started
9 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2000 | 2 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 3
CASI Pharmaceuticals, Inc. (6) · Memorial Sloan Kettering Cancer Center (3)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
Studies
Open first, then newest update. How each study uses mkc-1 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid TumorCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00003755Written as MKC-1
- Ro 31-7453 in Treating Patients With Metastatic Solid TumorsCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00014365Written as MKC-1
- Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00016250Written as MKC-1
- Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung CancerCompletedPhase 1/2CASI Pharmaceuticals, Inc.NCT00408226Written as MKC-1
- A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial CancerCompletedPhase 2CASI Pharmaceuticals, Inc.NCT00607607Written as MKC-1
- Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic CancerCompletedPhase 2CASI Pharmaceuticals, Inc.NCT00568646Written as MKC-1
- Phase 1 Study of MKC-1 in Patients With Advanced CancerCompletedPhase 1CASI Pharmaceuticals, Inc.NCT00656461Written as MKC-1
- A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1CompletedPhase 2CASI Pharmaceuticals, Inc.NCT00306631Written as MKC-1
- A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic MalignanciesCompletedPhase 1CASI Pharmaceuticals, Inc.NCT00506402Written as MKC-1
Codes
What other systems call mkc-1 · ClinicalTrials.gg INT004686
- UNII (FDA) DNZ11VPY7QMKC-1Confirmed FDA, NLM, Wikidata
- Wikidata Q27276500mkc-1Confirmed FDA, NLM, Wikidata
- NCI Thesaurus C2507MKC-1One source FDA
- DrugBank DB05608One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DNZ11VPY7Q | MKC-1 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27276500 | mkc-1 | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2507 | MKC-1 | One source FDA |
| DrugBank | DB05608 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.